Rohtak News Magazine

DelveInsight Business Research LLP

Exocrine Pancreatic Insufficiency Epi Market

The Exocrine Pancreatic Insufficiency (EPI) market report provides current treatment practices, emerging drugs, Exocrine Pancreatic Insufficiency (EPI) market share of the individual therapies, current and forecasted Exocrine Pancreatic Insufficiency (EPI) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Exocrine Pancreatic Insufficiency (EPI) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Exocrine Pancreatic Insufficiency (EPI) Market Outlook

The Exocrine Pancreatic Insufficiency (EPI) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Exocrine Pancreatic Insufficiency (EPI) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Exocrine Pancreatic Insufficiency (EPI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Exocrine Pancreatic Insufficiency (EPI) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Exocrine Pancreatic Insufficiency (EPI) 7MM market.

• The United States accounts for the largest market size of Exocrine Pancreatic Insufficiency (EPI), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
• The market size of Exocrine Pancreatic Insufficiency (EPI) in the seven major markets is USD 1,695.26 Million in 2017 for the study period (2017–2030).

Scope of the Report

• The report covers the descriptive overview of Exocrine Pancreatic Insufficiency (EPI) , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Exocrine Pancreatic Insufficiency (EPI) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Exocrine Pancreatic Insufficiency (EPI) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Exocrine Pancreatic Insufficiency (EPI) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Exocrine Pancreatic Insufficiency (EPI) market

Table of contents

1 Key Insights

2 Executive Summary

3 SWOT Analysis

4 Exocrine Pancreatic Insufficiency (EPI) Market Overview at a Glance

4.1 Market Share (%) Distribution of Exocrine Pancreatic Insufficiency (EPI) in 2017

4.2 Market Share (%) Distribution of Exocrine Pancreatic Insufficiency (EPI) in 2030

5 Disease Background and Overview: Exocrine Pancreatic Insufficiency (EPI)

5.1 Introduction

5.2 Biology and pathology of Exocrine Pancreatic Insufficiency

5.3 Pathophysiology of EPI

5.4 Causes and Risk Factors of EPI

5.4.1 EPI caused by pancreatic disorders

5.4.2 EPI caused by extrapancreatic disorders

5.5 Serum nutritional markers for prediction of pancreatic exocrine insufficiency in chronic pancreatitis

5.5.1 Disorders of Carbohydrate Metabolism

5.5.2 Disorders of Lipid Metabolism

5.6 Diagnosis

5.6.1 Fecal elastase-1 test (FE-1)

5.6.2 Serum trypsinogen

5.6.3 Fecal chymotrypsin

5.6.4 Breath tests

5.6.5 Coefficient of fat absorption (CFA)

5.6.6 Preoperative Evaluation

5.6.7 Direct pancreatic function test

5.6.8 Secretin-enhanced magnetic resonance cholangiopancreatography (MRCP)

5.6.9 Differential Diagnosis of exocrine pancreatic insufficiency

6 Recognized Establishments

7 Epidemiology and Patient Population

7.1 Key Findings

7.2 7 Major Markets

7.2.1 Prevalence of Causative Indications of EPI in the 7MM

7.2.2 Prevalence of Exocrine Pancreatic Insufficiency in the 7MM

8 Country-wise Epidemiology of Exocrine Pancreatic Insufficiency (EPI)

8.1 Assumption and Rationale

8.1 United States

8.1.1 Prevalence of Causative Indications of EPI in the United States

8.1.2 Prevalence of Exocrine Pancreatic Insufficiency in the United States

8.2 EU5 Countries

8.2.1 Assumption and Rationale

8.3 Germany

8.3.1 Prevalence of Causative Indications of EPI in Germany

8.3.2 Prevalence of Exocrine Pancreatic Insufficiency in Germany

8.4 France

8.4.1 Prevalence of Causative Indications of EPI in France

8.4.2 Prevalence of Exocrine Pancreatic Insufficiency in France

8.5 Italy

8.5.1 Prevalence of Causative Indications of EPI in Italy

8.5.2 Prevalence of Exocrine Pancreatic Insufficiency in Italy

8.6 Spain

8.6.1 Prevalence of Causative Indications of EPI in Spain

8.6.2 Prevalence of Exocrine Pancreatic Insufficiency in Spain

8.7 The United Kingdom

8.7.1 Prevalence of Causative Indications of EPI in the United Kingdom

8.7.2 Prevalence of Exocrine Pancreatic Insufficiency in the United Kingdom

8.8 Japan

8.8.1 Assumption and Rationale

8.8.2 Prevalence of Causative Indications of EPI in Japan

8.8.3 Prevalence of Exocrine Pancreatic Insufficiency in Japan

9 Treatment

9.1.1 Dietary management and lifestyle changes

9.1.2 Pancreatic enzyme replacement therapy (PERT)

9.1.3 Patient Journey of EPI with Gastrointestinal Disorders in Diabetes

10 Unmet Needs

11 Marketed Drugs

11.1 Key-cross Competition

11.2 Pertzye (pancrelipase): Digestive Care

11.2.1 Product Description

11.2.2 Regulatory Milestone

11.2.3 Other Developmental Activities

11.2.4 Safety and Efficacy

11.2.5 Product Profile

11.3 Creon (pancrelipase)/Lipacreon: AbbVie

11.3.1 Product Description

11.3.2 Regulatory Milestone

11.3.3 Other Developmental Activities

11.3.4 Safety and Efficacy

11.3.5 Pipeline Activity

11.3.6 Product Profile

11.4 Zenpep (pancrelipase): Nestle

11.4.1 Product Description

11.4.2 Regulatory Milestone

11.4.3 Other Developmental Activities

11.4.4 Safety and Efficacy

11.4.5 Product Profile

11.5 Pancreaze: Janssen Pharmaceuticals

11.5.1 Product Description

11.5.2 Regulatory Milestone

11.5.3 Other Developmental Activities

11.5.4 Safety and Efficacy

11.5.5 Product Profile

11.6 Viokace (pancrelipase): Aptalis Pharma/Forest Laboratories

11.6.1 Drug Description

11.6.2 Regulatory Milestones

11.6.3 Other Development Activities

11.6.4 Safety and Efficacy

11.6.5 Product Profile

11.7 RELiZORB: Alcresta Therapeutics

11.7.1 Product Description

11.7.2 Regulatory Milestone

11.7.3 Other Developmental Activities

11.7.4 Safety and efficacy

11.7.5 Product Profile

11.8 Ultresa (pancrelipase): Aptalis Pharma/Forest Laboratories

11.8.1 Drug Description

11.8.2 Regulatory Milestones

11.8.3 Other Development Activities

11.8.4 Safety and Efficacy

11.8.5 Product Profile

12 Emerging Drugs

12.1 Omeprazole: Chiesi Farmaceutici

12.1.1 Product Description

12.1.2 Clinical Development

12.1.3 Product Profile

12.2 MS1819-SD: AzurRx BioPharma

12.2.1 Product Description

12.2.2 Other Developmental Activities

12.2.3 Clinical Development

12.2.4 Product Profile

13 Exocrine Pancreatic Insufficiency (EPI): 7 Major Market Analysis

13.1 Key Findings

13.1 Total Market Size of Exocrine Pancreatic Insufficiency (EPI) in the 7MM Countries

13.1.1 Market Size by Therapies

14 Conjoint Analysis

15 7MM Market Outlook

16 United States Market Size

16.1.1 Total Market size of Exocrine Pancreatic Insufficiency (EPI)

16.1.2 Market Size by Therapies

17 EU-5 Market Size

17.1 Germany

17.1.1 Total Market size of Exocrine Pancreatic Insufficiency (EPI)

17.1.2 Market Size by Therapies

17.2 France

17.2.1 Total Market size of Exocrine Pancreatic Insufficiency (EPI)

17.2.2 Market Size of Exocrine Pancreatic Insufficiency (EPI) by Therapies

17.3 Italy

17.3.1 Total Market Size of Exocrine Pancreatic Insufficiency (EPI)

17.3.2 Market Size of Exocrine Pancreatic Insufficiency (EPI) by Therapies

17.4 Spain

17.4.1 Total Market Size of Exocrine Pancreatic Insufficiency (EPI)

17.4.2 Market Size of Exocrine Pancreatic Insufficiency (EPI) by Therapies

17.5 United Kingdom

17.5.1 Total Market Size of Exocrine Pancreatic Insufficiency (EPI)

17.5.2 Market Size by Therapies

17.6 Japan Market Size

17.6.1 Total Market Size of Exocrine Pancreatic Insufficiency (EPI)

17.6.2 Market Size by Therapies

18 Access and Reimbursement Overview: Exocrine Pancreatic Insuffficiency (EPI)

19 Case Reports

19.1 A Case Report of exocrine pancreatic insufficiency in palliative care patient

19.2 Case Report of a Patient with Pancreatic Exocrine Insufficiency and Enteral Feeding

19.3 Case Report of a Pancreatic Exocrine Insufficiency Patient with Systemic Edema after Pancreaticoduodenectomy

20 Market Drivers

21 Market Barriers

22 Appendix

23 DelveInsight Capabilities

24 Disclaimer

25 About DelveInsight

Request for sample pages @ Exocrine Pancreatic Insufficiency (EPI) Market

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/